Core Viewpoint - The domestic large-caliber artificial blood vessel project led by Yang Hongjun at Wuhan Textile University has entered the industrialization phase and will soon move into the registration stage [2] Company Involvement - Wanjian Medical (300888.SZ) confirmed on September 30 that it is collaborating with Wuhan Textile University on the artificial blood vessel project, which is currently in the animal testing phase [2] - The research and development cycle for the project is lengthy, and the company will communicate any breakthrough developments to the market in a timely manner [2]

Group 1 - The core issue raised by investors is the shift in the development stage of the artificial blood vessel project from "human trials" to "animal trials" after the collaboration with Wuhan Textile University in June 2023 [1] - The company, Steady Medical (300888.SZ), confirmed on September 23 that the artificial blood vessel project is planned to enter the animal trial phase, indicating a longer research and development cycle [1] - The company stated that any significant progress in the project will be communicated to the market in a timely manner [1]

每经AI快讯，有投资者在投资者互动平台提问：我希望能了解贵公司与武汉纺织大学徐卫林院士合作 的高仿生人造血管项目的最新进展。请问贵公司在该项目中是参股还是控股？此外，该项目对贵公司未 来业绩的潜在影响如何？ （文章来源：每日经济新闻） 稳健医疗（300888.SZ）7月30日在投资者互动平台表示，目前"人造血管项目"计划进入动物试验阶段， 项目研发周期较长，尚未产生业绩贡献。 ...